Dr. Kelly J. Yu is an Epidemiologist with the Early Detection Research Group for the Division of Cancer Prevention. Her research has primarily been focused on screening as a mode of cancer prevention. She is the Project Officer for the Prostate, Lung, Colorectal, and Ovarian Screening Trial, a large population-based randomized trial designed and sponsored by the National Cancer Institute to determine the effects of screening on cancer-related mortality and secondary endpoints in men and women aged 55 to 74.
Dr. Yu continues her work with the Division of Cancer, Epidemiology and Genetics to evaluate the utility of the Epstein-Barr virus as a biomarker for early detection of nasopharyngeal carcinoma (NPC) in general and for high-risk populations. She has maintained a long collaboration with researchers at the National Taiwan University and Academia Sinica to evaluate the genetic and environmental risk factors of NPC. More recently, she has become involved with a new longitudinal study that aims to investigate the early natural history of head and neck cancer precursor lesions and evaluate the predictive ability of biomarkers for progression. This study is important because there are currently no consensus guidelines for follow-up and treatment of patients with precursor lesions. Successful completion of this study will provide critical information regarding the most optimal screening intervals for follow-up of patients with precursor lesions, and the ideal way to identify patients for treatment.